Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.Journal of Pharmacokinetics and Pharmacodynamics|March 4, 2023
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug developmentAna Ruiz-Garcia, Paul Baverel, Dean Bottino, et al.Clinical Pharmacology and Therapeutics|October 19, 2022
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in UgandaKatherine Kay, Justin Goodwin, Hanna Ehrlich, et al.The Lancet. Oncology|July 10, 2009
Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II studySandrine Faivre, Eric Raymond, Eveline Boucher, et al.Anti-Cancer Drugs|January 24, 2018
Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancerChandrasekar Durairaj, Ana Ruiz-Garcia, Eric R Gauthier, et al.Cancer|February 7, 2014
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinibKaren L Reckamp, Giuseppe Giaccone, D Ross Camidge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.Investigational New Drugs|May 13, 2010
Phase II study of sunitinib as second-line treatment for advanced gastric cancerYung-Jue Bang, Yoon-Koo Kang, Won K Kang, et al.Pageof 4